Modality
ERT
MOA
KRASG12Di
Target
SOS1
Pathway
Amyloid
RettLN
Development Pipeline
Preclinical
~Nov 2021
→ ~Feb 2023
Phase 1
May 2023
→ Oct 2027
Phase 1Current
NCT07617357
2,427 pts·LN
2023-05→2027-10·Active
2,427 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-10-271.6y awayPh2 Data· LN
Trial Timeline
Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P1/2
Active
Catalysts
Ph2 Data
2027-10-27 · 1.6y away
LN
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07617357 | Phase 1/2 | LN | Active | 2427 | Safety |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| Ribofutibatinib | AstraZeneca | Phase 2/3 | SOS1 | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| Voxacagene | Gilead Sciences | Phase 2/3 | SOS1 | |
| SRP-9822 | Sarepta | Phase 3 | SOS1 | |
| Terarasimod | Krystal Biotech | Phase 1/2 | PI3Kα | |
| Fixaosocimab | TG Therapeutics | Phase 2/3 | SOS1 |